Longevity Technology

How near are we to technology that could allow humans to live much longer lives? Surprisingly close. Our goal is to unite innovators, researchers, insurers, policymakers, practitioners, and commentators to explore the emerging and rapidly expanding field of science and investment that will influence the future of our global population and economy: LONGEVITY.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#299064

United States

#108569

Health/Health

#2238

Traffic sources

Monthly visitors

Articles

Healthspan is the goal - function is the measure

2 days ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp Earlier this week, the XPRIZE Foundation announced the 40 semi-finalist teams in its $101 million Healthspan competition – a global initiative designed to catalyze scalable interventions that restore muscle, cognitive and immune function by at least a decade in adults aged 50 to 80.
Longevity investment more than doubles as sector shifts focus

3 days ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp After a year of fiscal contraction and economic caution, the longevity sector has staged a return to form – albeit not in the manner some might have expected. Rather than chasing exuberant deal volumes or early-stage gambles, investors in 2024 favored focus over fervor; capital flowed into companies positioned to advance beyond proof-of-concept, with discovery platforms and later-stage VC dominating the field.
HAYA Therapeutics harnesses the ‘dark genome’ against age-related diseases

4 days ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Precision medicine biotech HAYA Therapeutics has secured $65 million in Series A funding to accelerate the development of RNA-guided medicines that target chronic and age-related diseases by modulating the regulatory genome. The investment will enable the company to advance its lead therapeutic candidate into clinical trials for heart failure and to broaden its pipeline of therapies that target long non-coding RNAs (lncRNAs) in various disease contexts.
XPRIZE Healthspan names top 100 teams advancing healthy aging

4 days ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp The race to improve how long we live well has entered a new phase. XPRIZE Healthspan, the seven-year, $101 million global competition announced in late 2023, has unveiled its first cohort of semifinalists – 100 teams from 58 countries tasked with developing therapies to extend the years we spend in good health.
Alchemab and Lilly ink $415m neurodegeneration drug licensing deal

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp British biotech Alchemab Therapeutics this week announced a licensing agreement with pharma giant Eli Lilly for its lead investigational drug aimed at neurodegenerative conditions. The “IND-ready” drug, called ATLX-1282, is the first to emerge from Alchemab’s proprietary platform, which harnesses antibody responses from individuals who exhibit resilience to serious diseases.
UK NHS trains AI on entire population’s health data

1 week ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp In what may be a defining test for national-scale artificial intelligence in healthcare, the United Kingdom has trained a generative AI model on the medical histories of nearly its entire population. The model – named Foresight – was developed using deidentified NHS data from 57 million patients and is designed to predict more than a thousand future disease diagnoses, including hospital admissions, complications and major events such as myocardial infarction.
Hundred Health acquires BellSant to enhance AI-powered longevity platform

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp The AI-enabled personalized healthcare market is hotting up, with the likes of Function Health and Superpower both hitting the headlines recently. This week, another player emerged as AI-driven consumer health platform Hundred Health announced the acquisition of personalized health and wellness providerBellSant in an all-stock deal aimed at integrating a wealth of longevity research into its offering.
Hidden biological ‘language’ may hold the key to unlocking lifespan extension

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Scientists at the Sagol Center for Healthy Human Longevity at Bar-Ilan University have made progress in the quest to learn why some mammals have evolved to live much longer, and comparatively healthier, lives than others.
FDA clears Osteoboost wearable for treating low bone density

1 week ago | longevity.technology | Eleanor Garth

Get longevity news first on WhatsApp Osteoboost Health has announced the national availability of its newly FDA-cleared wearable device designed to treat low bone density – specifically osteopenia, a stage of bone thinning that precedes osteoporosis but which accounts for more than half of all fragility fractures. Osteoboost is the first prescription-only medical device of its kind cleared by the FDA to treat low bone density.
NewLimit lands $130m to advance epigenetic reprogramming platform

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech NewLimit has raised $130 million in Series B funding to advance its mission to extend human healthspan through epigenetic reprogramming. Founded with the goal of developing medicines that increase the number of healthy years in human life, NewLimit initially anticipated a long multi-year trajectory toward tangible scientific progress.